Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 362-367 |
| Journal | Annals of the Rheumatic Diseases |
| Volume | 75 |
| Issue number | 2 |
| Early online date | 4 Dec 2014 |
| DOIs | |
| Publication status | Published - Feb 2016 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1) : an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. / Ranganath, Lakshminarayan R; Milan, Anna M; Hughes, Andrew T; Dutton, John J; Fitzgerald, Richard; Briggs, Michael C; Bygott, Helen; Psarelli, Eftychia E; Cox, Trevor F; Gallagher, James A; Jarvis, Jonathan C; van Kan, Christa; Hall, Anthony K; Laan, Dinny; Olsson, Birgitta; Szamosi, Johan; Rudebeck, Mattias; Kullenberg, Torbjörn; Cronlund, Arvid; Svensson, Lennart; Junestrand, Carin; Ayoob, Hana; Timmis, Oliver G; Sireau, Nicolas; Le Quan Sang, Kim-Hanh; Genovese, Federica; Braconi, Daniela; Santucci, Annalisa; Nemethova, Martina; Zatkova, Andrea; McCaffrey, Judith; Christensen, Peter; Ross, Gordon; Imrich, Richard; Rovensky, Jozef.
In: Annals of the Rheumatic Diseases, Vol. 75, No. 2, 02.2016, p. 362-367.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1)
T2 - an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment
AU - Ranganath, Lakshminarayan R
AU - Milan, Anna M
AU - Hughes, Andrew T
AU - Dutton, John J
AU - Fitzgerald, Richard
AU - Briggs, Michael C
AU - Bygott, Helen
AU - Psarelli, Eftychia E
AU - Cox, Trevor F
AU - Gallagher, James A
AU - Jarvis, Jonathan C
AU - van Kan, Christa
AU - Hall, Anthony K
AU - Laan, Dinny
AU - Olsson, Birgitta
AU - Szamosi, Johan
AU - Rudebeck, Mattias
AU - Kullenberg, Torbjörn
AU - Cronlund, Arvid
AU - Svensson, Lennart
AU - Junestrand, Carin
AU - Ayoob, Hana
AU - Timmis, Oliver G
AU - Sireau, Nicolas
AU - Le Quan Sang, Kim-Hanh
AU - Genovese, Federica
AU - Braconi, Daniela
AU - Santucci, Annalisa
AU - Nemethova, Martina
AU - Zatkova, Andrea
AU - McCaffrey, Judith
AU - Christensen, Peter
AU - Ross, Gordon
AU - Imrich, Richard
AU - Rovensky, Jozef
N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
PY - 2016/2
Y1 - 2016/2
N2 - Alkaptonuria (AKU) is a serious genetic disease characterised by premature spondyloarthropathy. Homogentisate-lowering therapy is being investigated for AKU. Nitisinone decreases homogentisic acid (HGA) in AKU but the dose-response relationship has not been previously studied.
AB - Alkaptonuria (AKU) is a serious genetic disease characterised by premature spondyloarthropathy. Homogentisate-lowering therapy is being investigated for AKU. Nitisinone decreases homogentisic acid (HGA) in AKU but the dose-response relationship has not been previously studied.
U2 - 10.1136/annrheumdis-2014-206033
DO - 10.1136/annrheumdis-2014-206033
M3 - Article
C2 - 25475116
VL - 75
SP - 362
EP - 367
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 2
ER -